Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Wang G, Li Y, Xiong C, McDade E, Clifford DB, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Libre-Guerra JJ, McCullough A, Joseph-Mathurin N, Chen CD, Mummery C, Wendelberger BA, Gauthier S, Masellis M, Holdridge KC, Yaari R, Chatterjee S, Sims J, Delmar P, Kerchner GA, Bittner T, Hofmann C, Bateman RJ; DIAN‐TU Study Team. Wang G, et al. Among authors: kerchner ga. Alzheimers Dement (Amst). 2022 Nov 3;14(1):e12367. doi: 10.1002/dad2.12367. eCollection 2022. Alzheimers Dement (Amst). 2022. PMID: 36348972 Free PMC article.
Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).
Mazer NA, Hofmann C, Lott D, Gieschke R, Klein G, Boess F, Grimm HP, Kerchner GA, Baudler-Klein M, Smith J, Doody RS; Alzheimer's Disease Neuroimaging Initiative. Mazer NA, et al. Among authors: kerchner ga. Alzheimers Dement. 2023 Jun;19(6):2287-2297. doi: 10.1002/alz.12877. Epub 2022 Dec 1. Alzheimers Dement. 2023. PMID: 36454709
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Brockmann K, Svoboda H, Trundell D, Monnet A, Doody R, Fontoura P, Kerchner GA, Brundin P, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: kerchner ga. Nat Med. 2024 Apr;30(4):1096-1103. doi: 10.1038/s41591-024-02886-y. Epub 2024 Apr 15. Nat Med. 2024. PMID: 38622249 Free PMC article.
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
Boess FG, Scelsi MA, Grimmer T, Perry RJ, Tonietto M, Klein G, Hofmann C, Salami M, Wojtowicz J, Lansdall CJ, Lane C, Kerchner GA, Smith J, Doody RS. Boess FG, et al. Among authors: kerchner ga. J Prev Alzheimers Dis. 2024;11(3):537-548. doi: 10.14283/jpad.2024.60. J Prev Alzheimers Dis. 2024. PMID: 38706270 Clinical Trial.
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).
Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS. Neve A, et al. Among authors: kerchner ga. J Alzheimers Dis. 2024;101(1):353-367. doi: 10.3233/JAD-240221. J Alzheimers Dis. 2024. PMID: 39177596 Free PMC article. Clinical Trial.
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).
Boada M, Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS. Boada M, et al. Among authors: kerchner ga. J Alzheimers Dis. 2024 Dec 16:13872877241303644. doi: 10.1177/13872877241303644. Online ahead of print. J Alzheimers Dis. 2024. PMID: 39686620
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
Wilson EN, Young CB, Ramos Benitez J, Swarovski MS, Feinstein I, Vandijck M, Le Guen Y, Kasireddy NM, Shahid M, Corso NK, Wang Q, Kennedy G, Trelle AN, Lind B, Channappa D, Belnap M, Ramirez V, Skylar-Scott I, Younes K, Yutsis MV, Le Bastard N, Quinn JF, van Dyck CH, Nairn A, Fredericks CA, Tian L, Kerchner GA, Montine TJ, Sha SJ, Davidzon G, Henderson VW, Longo FM, Greicius MD, Wagner AD, Wyss-Coray T, Poston KL, Mormino EC, Andreasson KI. Wilson EN, et al. Among authors: kerchner ga. Alzheimers Res Ther. 2022 Nov 12;14(1):172. doi: 10.1186/s13195-022-01116-2. Alzheimers Res Ther. 2022. PMID: 36371232 Free PMC article.
Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum.
Trelle AN, Young CB, Vossler H, Ramos Benitez J, Cody KA, Mendiola JH, Swarovski MS, Guen YL, Feinstein I, Butler RR 3rd, Channappa D, Romero A, Park J, Shahid-Besanti M, Corso NK, Chau K, Smith AN, Skylar-Scott I, Yutsis MV, Fredericks CA, Tian L, Younes K, Kerchner GA, Deutsch GK, Davidzon GA, Sha SJ, Henderson VW, Longo FM, Greicius MD, Wyss-Coray T, Andreasson KI, Poston KL, Wagner AD, Mormino EC, Wilson EN. Trelle AN, et al. Among authors: kerchner ga. Alzheimers Dement. 2024 Dec 23. doi: 10.1002/alz.14442. Online ahead of print. Alzheimers Dement. 2024. PMID: 39713875
79 results